Loading company…
Riskpilot
← Back to search
Sign in
Get full access
PROVECTUS PHARMA INTERNATIONAL AS
AS
Active
Org 930384070
Slogumveien 99, 2015 Leirsund
Retail sale of other food · NACE 4727
Est. 2022
0 employees
Watchlist
Share
Overview
Financials
People & ownership
Related companies
Revenue 2024
NOK 0
EBITDA margin
—
-193% vs 2023
Equity ratio
51.1%
Financial strength
Net profit 2024
NOK -47K
-197% vs 2023
EBITDA — year on year
NOK millions
0M
-0M
-1M
-1M
-1M
0M
2023
0M
0%
2024
Key figures
Annual report 2024
Revenue
NOK 0
—
EBITDA
NOK -47K
-193%
Net profit
NOK -47K
-197%
Total assets
NOK 581K
+65%
Equity
NOK 297K
-14%
Employees
0
—
Company information
Legal name
PROVECTUS PHARMA INTERNATIONAL AS
Org number
930384070
Legal form
Aksjeselskap
NACE code
4727 · Retail sale of other food
Founded
8. desember 2022
Share capital
NOK 30 000
Employees
0
VAT registered
No
Audit selected
No
Last report
2024-12-31
Financial year
January – December
Signatory rights
Styrets medlemmer hver for seg. Styrets leder alene.
Company purpose
Investering i aksjer, både noterte og unoterte, deltakelse i andre selskaper og investering i fast eiendom, og annet som hører naturlig til.
Contact
Address
Slogumveien 99, 2015 Leirsund
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
Visit risika.com
Explore
Companies in Retail sale of other food
Companies in Lillestrøm
All Norway companies
Revenue
NOK millions
0M
0M
1M
1M
1M
0M
2023
0M
2024
EBITDA
NOK millions
0M
0M
1M
1M
1M
0M
2023
0M
2024
Income statement
NOK thousands
Item
2023
2024
Revenue
0
0
Staff expenses
−0
−0
EBITDA
−16
−47
Depreciation & amort.
−0
−0
EBIT
−16
−47
Net financials
0
−1
Profit before tax
−16
−47
Tax
−0
−0
Net profit
−16
−47
Balance sheet
NOK thousands
Item
2023
2024
Total assets
352
581
Equity
344
297
Long-term debt
0
0
Short-term debt
8
284
Total debt
8
284
Financial ratios
5-year trend
EBITDA margin
-4668500.0%
This company
15.8%
Market median
-29547568% vs market
2023
2024
Equity ratio
51.1%
This company
38.2%
Market median
+34% vs market
2023
2024
Return on equity
-15.9%
This company
18.4%
Market median
-186% vs market
2023
2024
Net profit margin
-4722900.0%
This company
8.1%
Market median
-58307507% vs market
2023
2024
Asset turnover
0.00×
This company
1.12×
Market median
-100% vs market
2023
2024
Debt / equity
0.96×
This company
0.62×
Market median
+55% vs market
2023
2024
Annual reports & filings
Annual report 2024
Filed via Brønnøysundsregistrene · Period 2024-01-01 – 2024-12-31
View
PDF
Annual report 2023
Filed via Brønnøysundsregistrene · Period 2022-10-02 – 2023-12-31
View
PDF
Management
Actively employed in the business
No data on file.
Board of directors
Non-executive oversight
Name
Role
Member since
Current (3)
RL
Ronny Licina Steng
Board of Directors
2022
JA
Jarle André Nummestad
Chairman
2022
EL
Eddy Licina Steng
Board of Directors
2022
Shareholders
As of last annual report
Shareholder
Type
Ownership
Votes
Since
Licina Holding As
Company
30%
30%
2024
Nummis Holding As
Company
30%
30%
2024
Fantastisk As
Company
30%
30%
2024
Slinning Holding As
Company
10%
10%
2024
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive.
Learn more
.
Company hierarchy
Slinning Holding As
PROVECTUS PHARMA INTERNATIONAL AS
(this company)
PROVECTUS PHARMA NORDIC AS
Board network connections
Board members of PROVECTUS PHARMA INTERNATIONAL AS also hold positions in
0
other companies.
Person
Role here
Other companies
Ronny Licina Steng
Board of Directors
0 companies
Jarle André Nummestad
Chairman
0 companies
Eddy Licina Steng
Board of Directors
0 companies